Business Wire

Terraformation Officially Launches Terraware, Closing the Technology Gap in Global Reforestation

18.9.2024 14:00:00 CEST | Business Wire | Press release

Share

Terraware is a first-of-its-kind, open-source, comprehensive forest management software, built by foresters, for foresters, to enhance efficiency and reporting

Today, Terraformation, a native forest restoration company dedicated to addressing climate change, announced the official launch of Terraware, its global forestry management platform. Built by foresters, for foresters, the software enables forestry teams worldwide to manage all stages of restoration projects—from site planning to seed collection, nursery management, carbon tracking, and planting. The robust platform streamlines data collection and reporting, and bridges the gap between remote sensing and ground data, providing a clearer picture of forest health and progress.

“Large-scale reforestation is labor-intensive, and there has been a noticeable technology gap within the forestry industry. Terraware translates science-backed methods for managing and measuring forestry projects into simple, accessible data and digestible action steps for forestry organizations,” said Yishan Wong, Founder and CEO of Terraformation. “This type of technology is a mission-critical component in the global effort to combat climate change through reforestation, and that is why we made a conscious decision to make it available to everyone.”

Restoring a biodiverse forest involves a complex and time-consuming set of tasks: mapping planting areas, sourcing native seeds, managing nursery operations, tracking planting progress, adapting to changing conditions, and more. Through years of extensive research and real-world forestry project experience, Terraformation identified the need for advanced, user-friendly tools to support the entire reforestation process. What began as a tool for seed collection has evolved into a comprehensive forest management platform that can be leveraged by forestry teams as well as project investors and funders.

Terraware was developed and tested with key partners, and over 300 organizations in 60 countries have registered to use Terraware. Key software features include:

  • Project Management Tools for Forest Restoration Teams: Terraware streamlines project planning, monitoring, and reporting processes, reducing administrative burdens and freeing up resources to focus on fieldwork.
  • Seamless Reporting for Donors and Investors: With tools like automated reporting templates and a funder portal, Terraware ensures that all stakeholders have access to accurate, up-to-date information on project status, fostering trust and transparency, and enabling better decision-making. (Available to Terraformation’s Accelerator partners)
  • Survival Monitoring for Seed Bank and Nursery Managers: By providing detailed tracking and monitoring of plants as they move from seed germination to seedlings and eventually plants in the field, Terraware helps foresters optimize every part of their project, identify problems earlier, reduce waste, and lower costs.
  • Real-time Tracking for Field Technicians: Terraware’s ability to track data from seed to forest maturity allows foresters to make informed decisions and adapt management practices in response to on-the-ground realities, leading to more resilient forests and higher project success rates.

“The insights we gain from Terraware are invaluable. It not only simplifies our project tracking but has also empowered our team to make informed decisions, ensuring our restoration projects remain on course to meet their goals.” — Benson Tilya, Seed Bank Analyst and Conservation Manager, Saving Africa’s Nature (SANA)

Terraware is currently in use by forestry and conservation organizations, including participants in Terraformation’s Seed to Carbon Forest Accelerator, a biodiversity-focused, carbon-funded program that supports forestry teams with the skills, tools, and funding access to create investable projects. Terraformation recently welcomed seven teams from Brazil, Colombia, Ghana, Kenya, and Tanzania to its fourth cohort and is currently accepting applications for its next cohort of forestry teams.

Through Terraware, investors and corporate sustainability teams supporting Terraformation’s Accelerator projects have access to robust and transparent data, offering detailed real-time insights from the start of a high-quality, carbon-certified project, helping them feel confident in the success of their investments. The software provides plant tracking solutions that match the latest carbon methodologies from carbon certification bodies like Verra.

Terraware is accessible at https://terraware.io and as a mobile app (iOS and Android), with offline data collection options for essential features like seed collecting and plant tracking.

To learn more about Terraformation and its industry-leading software, visit: https://terraformation.com/terraware

About Terraformation

Terraformation is a native forest restoration company dedicated to addressing climate change by rapidly expanding large-scale biodiverse forest projects. Our portfolio of high-quality projects is designed to restore native forests that will remove high quantities of carbon dioxide from the atmosphere, renew ecosystems, enhance biodiversity and climate resilience, and produce multiple community benefits. Our project teams have planted over one million biodiverse and native trees, stored 131 million seeds, supported 19 forestry projects, and created over 700 jobs through reforestation efforts worldwide.

Our multifaceted approach equips local forestry teams with training, technology, and access to capital to ensure transparency and long-term success. By supporting our forestry projects, corporations can directly address climate change and offset carbon emissions while transforming ecosystems and communities.

Founded in 2020, Terraformation brings together experts in forest science, carbon markets, operations, and business development to offer a unique approach to accelerate scalable and effective climate solutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918844939/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye